How can lab digitalization and automation help pharmaceutical companies

The looming decline in patented drug revenues is projected to impact up to $150 billion by 2027¹, putting pharmaceutical companies under immense pressure to accelerate innovation. With research and development costs accounting for 20% to 30% of revenues, R&D holds significant potential to leverage efficiency gains by automating and digitalizing lab processes. This whitepaper delves into how transforming traditional processes into automated, digitally driven workflows builds the foundation for AI-driven drug development, streamlining operations, reducing errors, and accelerating time-to-market.

For pharmaceutical companies, integrating disparate llab devices and systems, digitalizing and automating sample and data flow, and building fully integrated lab infrastructures is not just an option but a strategic imperative. By embracing lab digitalization and automation, pharmaceutical companies can minimize errors in daily lab routines, improve utilization of facilities, improve compliance and create a solid foundation for a transformation from traditional wet-lab driven processes to autonomous data-driven labs.²

Discover expert insights on the following topics in our whitepaper:

• In which digital maturity stage is your lab and what are high-level steps on the journey to fully digitalized and automated processes?
• What are the key obstacles in digitalizing lab environments, and how can they be overcome?
• Which strategies can minimize risks during the digital transformation of labs?
• How can standardization drive vendor-agnostic integration and automation?